L-carnitine supplement in end-stage liver disease adult patients

To survey the effect of L-carnitine supplement on frailty index in liver cirrhotic adult patients and compare to control group: A double-blind randomized control trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200628047940N2

Enrollment

Registered

2022-06-14

Start date

2022-01-30

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cirrhosis. K74- Fibrosis and cirrhosis of liver › 2022 ICD-10-CM Diagnosis Code K74.69.

Interventions

Intervention 1: The intervention group receives the L-carnitine supplement (b-hydroxy-gN-trimethylamino-butyric acid), an essential nutrient in the diet. The main function of L-carnitine in cellular e

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Adult patients(18-50 years old) Cirrhotic patients

Exclusion criteria

Exclusion criteria: Overt hepatic encephalopathy Consumption of L-carnitine supplement in the last year Hepatocellular carcinoma Decompensated cirrhosis MELD more than 20 HbA1c more than7

Design outcomes

Primary

Measure	Time frame
?Fraility. Timepoint: before intervention, after 2 months. Method of measurement: Liver frailty index. The liver frailty index will be used in the evaluation of frailty in patients with cirrhosis. This criterion consists of three parts. The Frilati Liver Index consists of three performance-based tests (grip strength, chair stands, and balance), a tool that measures physical function specifically in patients with cirrhosis.	—

Measure

Time frame

?Fraility. Timepoint: before intervention, after 2 months. Method of measurement: Liver frailty index. The liver frailty index will be used in the evaluation of frailty in patients with cirrhosis. This criterion consists of three parts. The Frilati Liver Index consists of three performance-based tests (grip strength, chair stands, and balance), a tool that measures physical function specifically in patients with cirrhosis.

—

Secondary

Measure	Time frame
Hepatic encephalopathy. Timepoint: Before intervention and 2, months after intervention. Method of measurement: Clinical examination, and lab data.;Creatinine level. Timepoint: before intervention, and 2 months after intervention. Method of measurement: lab data.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNasrin Motazedian

Shiraz University of Medical Sciences

motazediann@yahoo.com+98 71 3628 1529

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026